In case you missed it in @ACR_Journals: HCQ for 1y does not prevent RA development in people with CCP3 >2x ULN, either: - during 1y of treatment - in 2y follow-up https://t.co/gtzNiSmutb but StopRA will give us plenty of insights - data is never wasted #ACR25 ABST1674 @RheumNow https://t.co/DDZib5VGtX

• A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid art…
• https://x.com/drdavidliew/status/1982874509758902603/photo/1

In the IMPACT trial (Abs 0855), certolizumab met its primary endpoint: <20% had an adverse pregnancy outcome (APO) among females w/ APS & prior APO. ✅ 94% live births, all survived to discharge 📈 Median GA: 37 wks (no APO) vs 31 wks (APO) @RheumNow #ACR25

Did we need a 2nd Interception RCT of HCQ in Pre-RA? Unsure but in any case, it does not work either STOPRA CCP3+>=2 ind 71 HCQ and 74 PBO 36 months RA conversion Dr Deane's take: "probably wrong drug rather than wrong timing" #ACR25 @RheumNow #ABSTRACT1674 https://t.co/jysdo8iz7v

• https://x.com/AurelieRheumo/status/1982874833257152964/photo/1

Like PEXIVAS steroid taper, this is something we need an online resource to check each time. Its complicated, but feels "right". @RheumNow #ACR25 https://t.co/QAgSQB9XMQ

• https://twitter.com/Yuz6Yusof/status/1982823893199880429

In a cohort of 269,304 IBD patients, NSAID use showed a small increase in IBD-related hospitalisation (HR 1.08), meeting non-inferiority threshold (HR <1.2). No risk in UC (HR 0.96); modest risk in Crohn’s (HR 1.16). Relooks at the current paradigm of blanket NSAID avoidance in https://t.co/O8MWg1BP50

• https://x.com/synovialjoints/status/1982862356670480474/photo/1

56 pts w/tracheobronchial stenosis in GPA, highly frustrating disease manifestation Not surprising to see severe dx & prior intralesional tx assoc with incidence (ie necessity) of tracheal dilation Leflunomide protective? Have others seen this? #ACR @RheumNow Abstr#1596 https://t.co/djJXnAkxnv

• https://x.com/EBRheum/status/1982860846771437709/photo/1

In a prespecified exploratory analysis of REGENCY trial data by DrRovin et al, Bet. wks 24 and 76: Obinutuzumab ⬇️ LN flares vs. PBO (HR 0.44; p=0.0074) Pts on Obi had less unfavorable kidney outcomes vs. PBO (HR 0.37; p=0.0039) Addtl tx option for LN #ACR25 @RheumNow Abs1521 https://t.co/N5K9Nzh71E

• https://x.com/RHEUMarampa/status/1982844740291952655/photo/1

Simko et al. 6-monthly vs 3-monthly MTX lab monitoring. 3821 patients. Appears to be no difference. Potential for significant cost-savings and reduced burden to patients. @RheumNow #ACR25 Abstr#1370 #ACRbest https://t.co/G3tNQq8qXT

• https://x.com/RichardPAConway/status/1982844488977437109/photo/1

Infection data from SELECT-GCA: Glucocorticoids seem to drive overall infectious risk UPA use associated with higher zoster - vaccinate!! @RheumNow #ACR25 Abst# 0895 https://t.co/ueVbFPxG0Q

• https://x.com/Dr_Brian_MD/status/1982843521112641587/photo/1

Post Hoc analysis from SELECT-GCA Increased rate of herpes zoster for 26wk steroid-UPA 15mg (7.3% vs 4.2% 52wk steroid-plbo) but lower rate of SERIOUS infections (7.9% vs 12.7% 52wk steroid-plbo) Zoster risk is real; steroids are the bigger problem @Rheumnow #ACR25 Abstr#0895 https://t.co/IKzO2J4hLH

• https://x.com/EBRheum/status/1982839959070687309/photo/1
• https://x.com/EBRheum/status/1982839959070687309/photo/1
• https://x.com/EBRheum/status/1982839959070687309/photo/1

Concerns using dupilumab in EGPA due to secondary eosinophilia What about when combined with IL-5 therapy? 16 pt on dupi + IL5 agent - if dupi alone caused eosinophilia -> quelled by IL-5 - no eosinophilia when dupi added to IL-5 - effective but slow @RheumNow #ACR25 Abst 1605

Liraglutide had decreased synovial inflammation and fibrosis in mouse models, however dexamethasone didnt have changes in fibrosis scores Abst#1734 #ACR25 @RheumNow https://t.co/O4JYGtDD5N

• https://x.com/bella_mehta/status/1982837788166017285/photo/1

Analysis from FVSG identified 36pts with anti-rituximab antibodies In AAV, lookout for this in pts who are MPO+ & w/higher CD19 at 6 mos. Worse relapse free survival in both AAV & CRYO! @TerrierBen can you share the prevalence of these abs? #ACR25 @RheumNow #ACRBest abstr#1604 https://t.co/Nyx6JxbvUk

• https://x.com/EBRheum/status/1982837442140148004/photo/1
• https://x.com/EBRheum/status/1982837442140148004/photo/1

Ultra-low dose (ULD) RTX in AAV maintenance 200mg q6 mo vs. 500mg q6 mo interim analysis No major difference in infection risk or hypogammaglobulinemia thus far but both doses appeared similarly efficacious #ACR25 @rheumnow Abst 1609 https://t.co/ZGYNVGY3dr

• https://x.com/Dr_Brian_MD/status/1982835119527493687/photo/1

NEREA registry study on mortality in progressive pulmonary fibrosis in SARD-ILD. 158 patients. Median survival 7.8 years. DMARD use associated improved mortality. @RheumNow #ACR25 Abstr#1024 https://t.co/rK1caGi2r4

• https://x.com/RichardPAConway/status/1982833416073625649/photo/1